Ristocetin

WikiDoc Resources for Ristocetin
Articles
Most recent articles on Ristocetin Most cited articles on Ristocetin Review articles on Ristocetin Articles on Ristocetin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ristocetin Images of Ristocetin Photos of Ristocetin Podcasts & MP3s on Ristocetin Videos on Ristocetin
Evidence Based Medicine
Cochrane Collaboration on Ristocetin Bandolier on Ristocetin TRIP on Ristocetin
Clinical Trials
Ongoing Trials on Ristocetin at Clinical Trials.gov Trial results on Ristocetin Clinical Trials on Ristocetin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ristocetin NICE Guidance on Ristocetin NHS PRODIGY Guidance FDA on Ristocetin CDC on Ristocetin
Books
Books on Ristocetin
News
Ristocetin in the news Be alerted to news on Ristocetin News trends on Ristocetin
Commentary
Blogs on Ristocetin
Definitions
Definitions of Ristocetin
Patient Resources / Community
Patient resources on Ristocetin Discussion groups on Ristocetin Patient Handouts on Ristocetin Directions to Hospitals Treating Ristocetin Risk calculators and risk factors for Ristocetin
Healthcare Provider Resources
Symptoms of Ristocetin Causes & Risk Factors for Ristocetin Diagnostic studies for Ristocetin Treatment of Ristocetin
Continuing Medical Education (CME)
CME Programs on Ristocetin
International
Ristocetin en Espanol Ristocetin en Francais
Business
Ristocetin in the Marketplace Patents on Ristocetin
Experimental / Informatics
List of terms related to Ristocetin

Ristocetin is an antibiotic, obtained from Amycolatopsis lurida, previously used to treat staphylococcal infections. It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro, e.g. to diagnose von Willebrand disease (vWD) or the Bernard-Soulier syndrome. Platelet agglutination caused by ristocetin can occur only in the presence of large multimers of von Willebrand factor, so if ristocetin is added to blood lacking the factor (or its receptor -- see below), it will not coagulate.

In some types of vWD (types 2B and platelet-type), lower than normal amounts of ristocetin cause platelet aggregation when the patient's platelet-rich plasma is used. This paradox is explained by these types having gain-of-function mutations which cause the vWD high molecular-weight multimers to bind more tightly to their receptors on platelets (the alpha chains of glycoprotein Ib (GPIb) receptors). In the case of type 2B vWD, the gain-of-function mutation involves von Willebrand's factor (VWF gene), and in platelet-type vWD, the receptor is the object of the mutation (GPIb). This increased binding causes vWD because the high-molecular weight multimers are removed from circulation in plasma since they remain attached to the patient's platelets. Thus, if the patient's platelet-poor plasma is used, the ristocetin cofactor assay will not agglutinate "standardized (ie., pooled platelets from normal donors which are fixed in formalin)" platelets, similar to the other types of vWD.

In all forms of the ristocetin assay, the platelets are fixed in formalin prior to the assay to prevent von Willebrand's factor stored in platelet granules from being released and participating in platelet aggregation. Thus, the ristocetin cofactor activity depends only upon high-molecular multimers of the factor present in circulating plasma.